Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Active immunotherapy reduces NOTCH3 deposition in brain capillaries in a CADASIL mouse model

DV. Oliveira, KG. Coupland, W. Shao, S. Jin, F. Del Gaudio, S. Wang, R. Fox, JW. Rutten, J. Sandin, H. Zetterberg, J. Lundkvist, SA. Lesnik Oberstein, U. Lendahl, H. Karlström

. 2023 ; 15 (2) : e16556. [pub] 20221216

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004224

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common monogenic form of familial small vessel disease; no preventive or curative therapy is available. CADASIL is caused by mutations in the NOTCH3 gene, resulting in a mutated NOTCH3 receptor, with aggregation of the NOTCH3 extracellular domain (ECD) around vascular smooth muscle cells. In this study, we have developed a novel active immunization therapy specifically targeting CADASIL-like aggregated NOTCH3 ECD. Immunizing CADASIL TgN3R182C150 mice with aggregates composed of CADASIL-R133C mutated and wild-type EGF1-5 repeats for a total of 4 months resulted in a marked reduction (38-48%) in NOTCH3 deposition around brain capillaries, increased microglia activation and lowered serum levels of NOTCH3 ECD. Active immunization did not impact body weight, general behavior, the number and integrity of vascular smooth muscle cells in the retina, neuronal survival, or inflammation or the renal system, suggesting that the therapy is tolerable. This is the first therapeutic study reporting a successful reduction of NOTCH3 accumulation in a CADASIL mouse model supporting further development towards clinical application for the benefit of CADASIL patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004224
003      
CZ-PrNML
005      
20230425141221.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.15252/emmm.202216556 $2 doi
035    __
$a (PubMed)36524456
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Oliveira, Daniel V $u Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000306222934
245    10
$a Active immunotherapy reduces NOTCH3 deposition in brain capillaries in a CADASIL mouse model / $c DV. Oliveira, KG. Coupland, W. Shao, S. Jin, F. Del Gaudio, S. Wang, R. Fox, JW. Rutten, J. Sandin, H. Zetterberg, J. Lundkvist, SA. Lesnik Oberstein, U. Lendahl, H. Karlström
520    9_
$a Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common monogenic form of familial small vessel disease; no preventive or curative therapy is available. CADASIL is caused by mutations in the NOTCH3 gene, resulting in a mutated NOTCH3 receptor, with aggregation of the NOTCH3 extracellular domain (ECD) around vascular smooth muscle cells. In this study, we have developed a novel active immunization therapy specifically targeting CADASIL-like aggregated NOTCH3 ECD. Immunizing CADASIL TgN3R182C150 mice with aggregates composed of CADASIL-R133C mutated and wild-type EGF1-5 repeats for a total of 4 months resulted in a marked reduction (38-48%) in NOTCH3 deposition around brain capillaries, increased microglia activation and lowered serum levels of NOTCH3 ECD. Active immunization did not impact body weight, general behavior, the number and integrity of vascular smooth muscle cells in the retina, neuronal survival, or inflammation or the renal system, suggesting that the therapy is tolerable. This is the first therapeutic study reporting a successful reduction of NOTCH3 accumulation in a CADASIL mouse model supporting further development towards clinical application for the benefit of CADASIL patients.
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a mozek $x metabolismus $7 D001921
650    12
$a CADASIL $x genetika $x terapie $7 D046589
650    _2
$a kapiláry $x metabolismus $7 D002196
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a aktivní imunoterapie $7 D016233
650    _2
$a mutace $7 D009154
650    _2
$a receptor Notch3 $x genetika $x metabolismus $7 D000071656
650    _2
$a receptory Notch $x metabolismus $7 D051880
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Coupland, Kirsten G $u Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000243201043
700    1_
$a Shao, Wenchao $u Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Jin, Shaobo $u Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden $u Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000290649246
700    1_
$a Del Gaudio, Francesca $u Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000183421377
700    1_
$a Wang, Sailan $u Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Fox, Rhys $u Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden $u Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Rutten, Julie W $u Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a Sandin, Johan $u Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden $u Alzecure Foundation, Huddinge, Sweden $u Alzecure Pharma, Huddinge, Sweden
700    1_
$a Zetterberg, Henrik $u Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden $u Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden $u Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK $u UK Dementia Research Institute at UCL, London, UK $u Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China
700    1_
$a Lundkvist, Johan $u Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden $u Alzecure Foundation, Huddinge, Sweden $u Sinfonia Biotherapeutics, Huddinge, Sweden
700    1_
$a Lesnik Oberstein, Saskia Aj $u Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands $1 https://orcid.org/0000000212688995
700    1_
$a Lendahl, Urban $u Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden $u Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000195438141
700    1_
$a Karlström, Helena $u Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000204982473
773    0_
$w MED00189522 $t EMBO molecular medicine $x 1757-4684 $g Roč. 15, č. 2 (2023), s. e16556
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36524456 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141218 $b ABA008
999    __
$a ok $b bmc $g 1924722 $s 1190433
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 15 $c 2 $d e16556 $e 20221216 $i 1757-4684 $m EMBO molecular medicine $n EMBO Mol Med $x MED00189522
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace